AI Summary
In this study, the safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, is examined in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). The drug targets the androgen receptor via a unique mechanism of AR degradation and antagonism. The study, known as CC-94676-PCA-001 (NCT04428788), is a phase 1 multicenter trial investigating the efficacy of BMS-986365 in patients with progressive mCRPC.
Metastatic castration-resistant prostate cancer (mCRPC) that progresses on androgen receptor pathway inhibitors (ARPIs) may continue to be driven by AR signaling. BMS-986365 is an orally administered ligand-directed degrader targeting the AR via a first-in-class dual mechanism of AR degradation and antagonism. CC-94676-PCA-001 (NCT04428788) is a phase 1 multicenter study of BMS-986365 in patients with progressive mCRPC.